Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Current Assets (2016 - 2025)

Historic Current Assets for Champions Oncology (CSBR) over the last 15 years, with Q4 2025 value amounting to $21.3 million.

  • Champions Oncology's Current Assets rose 5146.27% to $21.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $21.3 million, marking a year-over-year increase of 5146.27%. This contributed to the annual value of $22.4 million for FY2025, which is 6392.7% up from last year.
  • As of Q4 2025, Champions Oncology's Current Assets stood at $21.3 million, which was up 5146.27% from $21.0 million recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Current Assets registered a high of $22.4 million during Q2 2025, and its lowest value of $12.6 million during Q3 2021.
  • Over the past 5 years, Champions Oncology's median Current Assets value was $16.4 million (recorded in 2022), while the average stood at $16.8 million.
  • As far as peak fluctuations go, Champions Oncology's Current Assets soared by 7182.04% in 2021, and later tumbled by 3517.36% in 2024.
  • Champions Oncology's Current Assets (Quarter) stood at $13.7 million in 2021, then soared by 50.4% to $20.6 million in 2022, then tumbled by 31.98% to $14.0 million in 2023, then grew by 0.48% to $14.1 million in 2024, then soared by 51.46% to $21.3 million in 2025.
  • Its Current Assets stands at $21.3 million for Q4 2025, versus $21.0 million for Q3 2025 and $22.4 million for Q2 2025.